Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
- 6 October 2010
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (2) , 708-713
Abstract
Gemcitabine is widely used for the treatment of advanced biliary tract cancer (BTC) as first-line chemotherapy. However, there is no standard chemotherapy for patient with advanced BTC refractory to gemcitabine. We conducted a multicenter phase II study of S-1 monotherapy as second-line chemotherapy for patients with advanced BTC that were refractory to gemcitabine. S-1 was administered orally at a dose of 80 mg/m2 for 28 days, followed by 14 days of rest. This regimen was repeated every 6 weeks. Tumor response was assessed every two cycles using the Response Evaluation Criteria in Solid Tumors version 1.0. Twenty-two patients were enrolled between March 2007 and January 2010, with 14 patients (64%) representing cases of recurrence after surgery. The overall response rate was 22.7%, and the overall disease control rate was 50.0%. The median overall survival time was 13.5 months (95% CI, 7.1–23.1 months) and the median time-to-progression was 5.4 months (95% CI, 2.6–17.2 months). Grade 3/4 toxicities included neutropenia (5%) and anemia (5%). The most common non-hematological toxicities were nausea (27%), anorexia (55%), and pigmentation (32%). In conclusion, S-1 monotherapy is feasible and moderately efficacious second-line chemotherapy for advanced BTC.Keywords
This publication has 18 references indexed in Scilit:
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanBritish Journal of Cancer, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractorinessInvestigational New Drugs, 2010
- Efficacy and Safety of S-1 Monotherapy in Patients with Advanced Biliary Tract AdenocarcinomaOncology, 2009
- S-1 Monotherapy in Patients with Advanced Biliary Tract CancerOncology, 2009
- Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II studyBritish Journal of Cancer, 2008
- Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trialsBritish Journal of Cancer, 2007
- Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II TrialJournal of Clinical Oncology, 2005
- Gemcitabine and Cisplatin Combination Chemotherapy in Intrahepatic Cholangiocarcinoma as Second-line Treatment: Report of Four CasesJapanese Journal of Clinical Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000